|
ComVort Philadelphia creates Brand of the YearDudnyk blazes new trails and wins PM360 Brand of the Year...
December 2009
Philadelphia, PA—The innovative launch campaign for MiddleBrook Pharmaceuticals’ (NASDAQ: MBRK) Moxatag® (amoxicillin extended-release) Tablets was crowned Infectious Disease Brand of the Year by PM360 magazine. Dudnyk—the multichannel, healthcare communications agency—created the brand’s compelling identity. Using the bold imagery of molten ore poured into a “Moxatag®” mold with the words, “The First Once-Daily Amoxicillin Is Formed,” conveys the product’s newness and strength.
“We are honored that the Moxatag® launch has been recognized by PM360,” said Seung Baick, Group Product Director, MiddleBrook Pharmaceuticals. “Making Moxatag® a reality has been a long road for us. Thankfully, Dudnyk continually challenged us to think differently about branding. With Dudnyk leading the charge, we’ve created a brand that resonates with doctors, and that connection has yielded impressive market share gains for the brand.”
“Having our work recognized like this is a great honor,” echoed Frank Powers, President, Dudnyk. “We are proud of the bold solution we created for Moxatag®, creating striking visuals that communicate intrinsic brand values. We realize success is more than how and where we tell our story: it’s about igniting the energy within a brand, propelling it forward.”
 |
click to see the page in high resolution
|
About MiddleBrook Pharmaceuticals
MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. MiddleBrook’s proprietary delivery technology—PULSYS™—enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MiddleBrook’s near-term corporate strategy includes improving dosing regimens and/or reducing frequency of dosing to enhance patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets Keflex® (cephalexin, USP), the immediate-release brand of cephalexin, and Moxatag®—the first and only FDA-approved, once-daily amoxicillin. For more information about MiddleBrook, please visit www.middlebrookpharma.com
About Keflex®
Keflex®, 750 mg, MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc., Moxatag®, and Pulsys™ are our trademarks, and have been registered in the U.S. Patent and Trademark Office, or are the subject of pending U.S. trademark applications. Each of the other trademarks, tradenames, or service marks appearing in this document belongs to the respective holder, as used herein, except as otherwise indicated by the context. References to “we,” “us,” “our,” “MiddleBrook,” or the “Company,” refer to MiddleBrook Pharmaceuticals, Inc., and its subsidiaries.
About Moxatag®
Moxatag® (amoxicillin extended-release) Tablets, 775 mg, is a once-a-day extended-release formulation of amoxicillin for oral administration, consisting of three components: one immediate-release component and two delayed-release components. The three components of Moxatag® are combined in a specific ratio to prolong the release of amoxicillin compared to immediate-release amoxicillin. Moxatag® is intended to provide a lower treatment dose, once-daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes. For more information about Moxatag®, please visit Moxatag.com
For further information please contact:
Frank X. Powers | President
+1-267-532-1060
fpowers@dudnyk.com
--------------------------------------------------------------
ComVort Central Office
Brando Brandstäter | COO
+34.39.459.44.22
brando@comvort.com
|
